Compare Five9 Inc (FIVN) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Nuwellis Inc — how do they compare? Five9 Inc trades at $31.09 (market cap $2.44B), while Nuwellis Inc trades at $1.4 (market cap $542.80K). The key difference: Five9 Inc is far larger — about 4495.2× Nuwellis Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| FIVN | NUWE | |
|---|---|---|
Market Cap | $2.44B | $542.80K |
Sector | Technology | Technology |
52-Week High | $34.48 | $220.50 |
52-Week Low | $13.61 | $1.42 |
Enterprise Value | $2.59B | -$1.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $31.14, down 9.69% today but remains near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to 10% in Q2 2026, reaching $312.4 million, while the company maintains a solid gross margin of 54.91%. Recent management appointments and AI-driven subscription growth provide positive catalysts.
The outlook remains positive with 61% analyst buy ratings and a $32.67 consensus target offering 5% upside. However, elevated valuation multiples (P/E 47.99) and ongoing fiduciary investigations pose risks. The stock's trajectory depends on continued execution of AI revenue growth and margin expansion targets.
NUWE trades at $1.41, down 0.7% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with preliminary Q2 2026 revenue up 14% year-over-year, but remains unprofitable with a net income margin of -217.22%. Recent developments include a reverse stock split, new CEO appointment, and expansion of its Aquadex platform into new pediatric markets. Cash flow from operations is negative, though recent financing activities have provided capital.
The outlook is mixed: growth initiatives and analyst support offer potential, but persistent losses and high cash burn pose significant risks. Investors should weigh the company's expansion against its financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
